Public Release: 

Insilico to present at the 3rd Annual MAQC Society Conference

InSilico Medicine, Inc.

IMAGE

IMAGE: Quentin Vanhaelen, Ph.D., Director, Virtual Human Project at Insilico Medicine, to present 'Reproducibility and interpretability of DL models for drug discovery: Current challenges and prospects' at the 3rd Annual MAQC... view more 

Credit: Insilico Medicine

Tuesday, April 2, 2019 - Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery at the 3rd Annual MAQC Conference in Italy, April 8-10.

Deep Learning methods have proven to be an effective tool to optimize key steps of the drug discovery pipeline, such as target identification and design of molecular compounds with desired properties. However, the systematic application of DL within these fields and for high-stakes decisions in healthcare drives specific demands for better interpretability and reproducibility.

While the specificity of DL architectures and learning processes require adapted solutions, researches are currently undertaken to design computational methods and workflows which can be used to make these types of approaches more interpretable and guarantee that results are reproducible.

The presentation will focus on the aspects that make achieving reproducibility challenging, ways of resolving potential issues, as well as recent developments that aim at making DL models more interpretable.

"We are happy to present our latest research at the 3rd Annual MAQC Conference, which gathers the key longevity leaders. The topic of AI for Drug Discovery and Productive longevity is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area," said Quentin Vanhaelen, Ph.D., Director, Virtual Human Project at Insilico Medicine.

The focus of the MAQC 2019 meeting is the challenge of applying Artificial Intelligence and Machine Learning to biological, health, and medical problems, still adopting reproducible science principles for a medicine safely based on the trustworth and fair analysis of massive data. The event is held in Riva del Garda, Italy, on April 8-10, 2019.

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.

###

For further information, images or interviews, please contact:

Contact: Klug Gehilfe
ai@pharma.ai
Website: http://insilico.com/
Official website of the conference: https://maqc2019.fbk.eu/

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8.

Website: http://insilico.com/

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.